CC
BIO icon

Centiva Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Centiva Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,508
Closed -$505K – 1710
2024
Q3 		$505K Buy
+1,508
New +$479K 0.01% 1242
2023
Q3 		– Sell
-755
Closed -$286K – 1724
2023
Q2 		$286K Buy
755
+18
+2% +$7.33K 0.01% 1145
2023
Q1 		$353K Buy
+737
New +$345K 0.01% 980
2022
Q2 		– Sell
-952
Closed -$536K – 1693
2022
Q1 		$536K Buy
+952
New +$574K 0.01% 945
2021
Q3 		– Sell
-1,124
Closed -$724K – 1284
2021
Q2 		$724K Buy
1,124
+756
+205% +$460K 0.02% 692
2021
Q1 		$210K Buy
+368
New +$218K 0.01% 954

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Centiva Capital's BIO Position: Q4 2024 in Review

Centiva Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 1,508 shares — an estimated $505K sold.

Centiva Capital first reported a position in BIO in Q1 2021 and held it in 6 quarters. The position peaked at $724K in Q2 2021. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Centiva Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 1,508 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $505K.
  • Centiva Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 6 quarters.
  • Centiva Capital's Bio-Rad Laboratories Class A position peaked at $724K in Q2 2021.
  • 457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.